Q2 FY2026 EarningsQ2 FY26 results exceeded expectations across major metrics, with revenue of $382.5M vs. $379.5M expected and a surprise GAAP net income of $5.6M compared to an anticipated $93.1M loss. Growth was spearheaded by the Data Licensing segment, which surged 36% YoY, and a 31% increase in Oncology volume. Full-year FY26 revenue guidance was raised to $1.595B - $1.605B, signaling continued momentum in AI-driven precision medicine.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Tempus AI(TEM) the Revenue is 382.49 M (+21.56%), Beat estimate;the EBIT is -2.708 M (+84.1%), Beat estimate;the EPS is 0.03 (+112%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.38B21.56%
0.38B20.63%
+0.00B0.93%
EBITExceed expectations
-0.00B84.10%
-0.02B4.97%
+0.01B79.13%
EPSExceed expectations
0.03112.00%
-0.5185107.38%
+0.5485219.38%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf